SOUTH SAN FRANCISCO, Calif., July 5, 2022 /PRNewswire/ — Titan Prescription drugs, Inc. (NASDAQ: TTNP) (“Titan” or the “Corporate”) lately introduced that the U.S. Meals and Drug Management (“FDA”) has cleared its Investigational New Drug (“IND”) software for a Section 1 learn about of its six-month or longer subdermal components of nalmefene, an opioid antagonist, supposed for the prevention of relapse following opioid cleansing in adults with Opioid Use Dysfunction (“OUD”).
Kate Beebe DeVarney, Ph.D., President and Leader Running Officer of Titan, commented, “FDA clearance of the IND for our ProNeura®-based nalmefene implant marks the most important milestone in growing a unique product that can lend a hand solution the decision for long-term remedy choices in habit drugs. We’re very thankful for the enhance we gained from the Nationwide Institute for Drug Dependancy, or NIDA, that enabled us to satisfy this function.”
About Titan Prescription drugs
Titan Prescription drugs, Inc. (NASDAQ:TTNP), founded in South San Francisco, CA, is a construction degree corporate growing proprietary therapeutics with its ProNeura® long-term, steady drug supply generation. The ProNeura generation has the prospective for use in growing merchandise for treating various continual stipulations, the place keeping up constant, around-the-clock blood ranges of medicine might benefit the affected person and toughen clinical results. In December 2021, Titan commenced a procedure to discover and overview strategic choices to improve shareholder price.
For more info about Titan, please talk over with www.titanpharm.com.
Ahead-Taking a look Statements
This press free up might include “forward-looking statements” throughout the that means of Segment 27A of the Securities Act of 1933 and Segment 21E of the Securities Alternate Act of 1934. Such statements come with, however don’t seem to be restricted to, any statements when it comes to our product construction techniques and every other statements that don’t seem to be ancient info. Such statements contain dangers and uncertainties that would negatively have an effect on our industry, working effects, monetary situation and inventory worth. Elements that would reason precise effects to vary materially from control’s present expectancies come with the ones dangers and uncertainties when it comes to our talent to boost capital, the regulatory approval procedure, the advance, trying out, manufacturing and advertising and marketing of our drug applicants, patent and highbrow belongings issues and strategic agreements and relationships. We expressly disclaim any legal responsibility or enterprise to free up publicly any updates or revisions to any forward-looking statements contained herein to replicate any trade in our expectancies or any adjustments in occasions, stipulations or cases on which the sort of commentary is founded, excluding as required through regulation.
CONTACT:
Stephen Kilmer
Investor Family members
(650) 989-2215
[email protected]
SOURCE Titan Prescription drugs, Inc.
